Berkeley Heights, NJ - June 4, 2003-
Genta Incorporated (Nasdaq: GNTA) today announced its participation
at the Needham & Company Second Annual Biotechnology Conference
in New York, NY. William Keane, Genta's Chief Financial Officer,
will provide an update on the Company's late-stage development
program on Thursday, June 5, 2003 at 3:30 p.m. EST.
A live audio webcast of the presentation can be accessed through
Genta's Investor Relations site at:
http://www.genta.com/genta/InvestorRelation/relations.html
. A replay will be available for 90 days following the
presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on oligonucleotides (RNA/DNA-based medicines) and small
molecules. Genasense
TM
(oblimersen sodium), the Company's lead compound from its
oligonucleotide program, is being developed with Aventis and is
currently undergoing late-stage, Phase 3 clinical
testing. The leading drug in Genta's small molecule program is
Ganite
TM
(gallium nitrate injection), which the Company intends to launch
later this year for treatment of cancerrelated hypercalcemia that
is resistant to hydration. For more information about Genta, please
visit our website at:
http://www.genta.com/
.
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and
developments to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual
Report/Form 10-K
for 2002.
SOURCE: Genta Incorporated
